European Society of Cardiology Congress

Shorts

John Ostrominski, MD | Image Credit: Harvard Health

0:53

Overcoming the Complexity Paradox in Heart Failure Treatment

2 months ago

John Ostrominski, MD

0:53

Using Machine Learning to Personalize Patient Outreach

2 months ago

Ankeet Bhatt, MD, MBA

Sharmila Dorbala, MD, MPH | Image Credit: LinkedIn

1:17

The Limitations of Current Cardiac Amyloid Testing

2 months ago

Sharmila Dorbala, MD, MPH

1:00

A Breakthrough in Reducing Heart Disease Risk

2 months ago

Steven E. Nissen, MD, MACC

Ahmad Masri, MD, MS | Image Credit: OHSU

0:48

Aficamten Clinical Results: 53% of Patients See Multi-Domain Improvement

2 months ago

Ahmad Masri, MD, MS

Don't Miss a Beat: Vericiguat in Heart Failure - The VICTOR Trial

1:30

Don't Miss a Beat: Vericiguat and the VICTOR Trial, With Javed Butler, MD

a year ago

Muthiah Vaduganathan, MD, MPH(+1 more)

Latest Content

Finerenone vs. Eplerenone: Trial Shows Mixed Results

ByGale Scott

August 31st 2015

In heart failure patients with diabetes and/or chronic kidney disease, a new, non-steroidal mineralocorticoid receptor antagonist called finerenone was no more effective than the currently approved MRA eplerenone in reducing the heart failure biomarker N-terminal pro-B-type natriuretic peptide. But it had other benefits.

Q&A With Robert Giugliano From Brigham and Women's: PCSK9 Inhibitors Provide Hope for Cardiac Patients

ByAdam Hochron

August 30th 2015

It was less than two decades ago that researchers uncovered the role of PCSK9 in a person's body. In just the past few months two new medications have been developed that could go a long way in helping win the fight against bad cholesterol.